BODY COMPOSITION MONITORS ישראל - עברית - Ministry of Health

body composition monitors

אגנטק (1987) בע"מ - כלל האוכלוסיה - כלל הציבור

body composition measurment equi.+access ישראל - עברית - Ministry of Health

body composition measurment equi.+access

מדטכניקה בע"מ - רופא - מיכשור מדידה

ארומזין ישראל - עברית - Ministry of Health

ארומזין

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

טסיגנה 200 מג ישראל - עברית - Ministry of Health

טסיגנה 200 מג

novartis israel ltd - nilotinib as monohydrate - קפסולות - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

טסיגנה 150 מג ישראל - עברית - Ministry of Health

טסיגנה 150 מג

novartis israel ltd - nilotinib as hydrochloride monohydrate - קפסולות - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

זולאייר   150 מג ישראל - עברית - Ministry of Health

זולאייר 150 מג

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

לינפארזה 100 מג ישראל - עברית - Ministry of Health

לינפארזה 100 מג

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 100 mg - olaparib

לינפארזה 100 מג ישראל - עברית - Ministry of Health

לינפארזה 100 מג

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 100 mg - olaparib

לינפארזה 150 מג ישראל - עברית - Ministry of Health

לינפארזה 150 מג

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib

לינפארזה 150 מג ישראל - עברית - Ministry of Health

לינפארזה 150 מג

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib